Novartis Q1 Preview: Profits Still Under Pressure From Lockdown
Entresto Sales Should Be Strong But Cosentyx May Struggle
The company will review a challenging quarter next week when its financials will reveal that certain parts of the business are still feeling the effects of the COVID-19 pandemic, its eye drugs in particular.
You may also be interested in...
Novartis’s PSMA-targeted radioligand has improved overall survival and progression-free survival in top-line results from the Phase III VISION study in prostate cancer, cementing the company's pioneering role in the therapeutic area.
The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.
Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker